证券代码：300937 证券简称：药易购 公告编号：2025-037 四川合纵药易购医药股份有限公司 关于设立全资子公司暨取得营业执照的 自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、设立全资子公司的情况概述 四川合纵药易购医药股份有限公司（以下简称"公司"）全资子公司四川药 易购科技集团有限公司（以下简称"药易购科技集团"）、杭州扶摇数智科技有 限公司（以下简称"杭州扶摇"）共同投资设立四川蜀坦人工智能科技有限公司 （以下简称"蜀坦人工智能"），注册资本 1,000 万元，资金来源为药易购科技 集团、杭州扶摇自有资金。公司通过下属子公司持有蜀坦人工智能 100%股权， 蜀坦人工智能已于近日完成工商注册登记，并取得成都市金牛区政务服务管理和 行政审批局颁发的《营业执照》。 法定代表人：周欢 注册资本：1,000 万元人民币 注册地址：四川省成都市金牛区友联一街 8 号 7 栋 15 层 1503 号 经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；技术进出口；货物进出口；特殊医学用途配方食品销售；健康 ...

Core Points - Sichuan Shutan Artificial Intelligence Technology Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on various value-added telecommunications services and internet information services related to pharmaceuticals and medical devices [1][2] - The company is jointly held by Sichuan Yaoyigou Technology Group Co., Ltd., a subsidiary of Yaoyigou (300937), which holds an 80% stake [1][2] Company Information - The legal representative of the company is Zhou Huan, and it is currently in operation with a business registration valid until August 1, 2025 [2] - The company is located in Jin Niu District, Chengdu, Sichuan Province, and is classified under other technology promotion services [2] - The business scope includes technology services, medical device sales, and various other commercial activities [2] Shareholding Structure - Sichuan Yaoyigou Technology Group Co., Ltd. holds 80% of the shares, contributing 8 million yuan to the registered capital [2] - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. is also a significant shareholder with a 96.5667% stake, contributing 50 million yuan [2][3]

Core Insights - The stock price of Yaoyigou (300937) closed at 31.19 yuan on August 1, 2025, reflecting a 2.56% increase with a turnover rate of 8.9% and a trading volume of 55,800 hands, amounting to 174 million yuan in transaction value [1] Financial Performance - For Q1 2025, the company reported total revenue of 1.138 billion yuan, a year-on-year decrease of 8.06% - The net profit attributable to shareholders was 4.1837 million yuan, down 54.65% year-on-year - The net profit after deducting non-recurring items was 3.564 million yuan, a decrease of 41.49% year-on-year - The current ratio stood at 1.622, the quick ratio at 1.110, and the debt-to-asset ratio at 51.62% [1] Company Overview - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. was established in 2007 and is located in Chengdu, primarily engaged in the pharmaceutical manufacturing industry - The company has a registered capital of 956.67 million yuan and a paid-in capital of 507.8 million yuan - The legal representative of the company is Li Yanfei [1] Investment and Intellectual Property - The company has made investments in 25 enterprises and participated in 26 bidding projects - It holds 183 trademark registrations and 16 patents, along with 34 administrative licenses [2]

Core Viewpoint - The recent board restructuring at YaoYigou (300937) has sparked market interest, particularly with the appointment of Chen Shunjun as the new chairman, which raises expectations for the company's digital transformation achievements [1] Group 1: Leadership Changes - Chen Shunjun, born in 1977, has extensive experience in artificial intelligence, big data, and strategic planning, which is expected to enhance the company's digital transformation efforts [1] - The independent director team has been significantly adjusted, with three university professors joining, bringing expertise in accounting, law, and business, potentially broadening the company's strategic vision [1] - Wang Yadong has been appointed as the head of auditing, holding qualifications as a sponsor representative and a registered accountant, with prior experience in major financial institutions [1] Group 2: Audit Committee Expansion - The audit committee has been expanded from three to five members, now including Li Yanfei (director and actual controller), Zhao Peipei (employee representative director), and three independent directors, with Gan Shengdao serving as the chairman [2] Group 3: Internal Control and Financial Performance - YaoYigou has emphasized internal control, continuously improving its internal control systems and enhancing internal audit supervision to prevent fund misuse [3] - The company has reported stable revenue performance, with revenues exceeding 4 billion yuan in both 2023 and 2024 [4]

Core Viewpoint - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. has appointed Chen Shunjun as the new chairman and general manager, indicating a strategic shift towards developing an industrial internet platform in the healthcare sector [1] Group 1: Leadership Changes - The company held its first meeting of the fourth board of directors on July 30, where Chen Shunjun was appointed as chairman and general manager [1] - This leadership change reflects the company's commitment to enhancing its management and operational capabilities [1] Group 2: Strategic Developments - The company is leveraging its established presence in the outpatient pharmaceutical distribution market to create a comprehensive health ecosystem [1] - Ongoing transformations include upgrades to the business team, management structure, and increased investment in research and development [1] - The appointment of Chen Shunjun, who has expertise in artificial intelligence, big data, and strategic planning, underscores the company's focus on advancing its industrial internet strategy [1]

Core Viewpoint - The recent board restructuring at Sichuan Hezhong Yaoyigou Co., Ltd. marks a strategic shift towards technology-driven growth and diversified ecosystem development under the leadership of Chen Shunjun, who has taken over as Chairman and continues as General Manager [1][2][3]. Group 1: Leadership Transition - Chen Shunjun's promotion from Vice Chairman to Chairman signals a strategic focus on technology integration and capital operations, moving from "scale expansion" to "ecosystem development" [2][3]. - The previous Chairman, Li Yanfei, will continue to leverage his extensive resources in the pharmaceutical distribution sector to support the company [2]. Group 2: Strategic Developments - Under Chen's leadership, the company is enhancing its industrial ecosystem by integrating smart technology, e-commerce, artificial intelligence, and big data into a "pharmaceutical + technology" dual-drive model [3]. - The company is accelerating capital operations through investments and collaborations in health, traditional Chinese medicine, and supply chain projects, aiming to establish a second growth curve [3]. Group 3: Governance Structure - The new board consists of nine members, including independent directors with diverse backgrounds in finance, law, and marketing, which will enhance compliance and strategic decision-making [4]. - The establishment of a Strategic and Development Committee led by Chen Shunjun emphasizes the company's commitment to both core business and strategic expansion [4]. Group 4: Management Team Dynamics - The management strategy focuses on "pharmaceutical + technology," "platform + ecosystem," and "self-operated + empowered" models, aiming to build a differentiated competitive advantage [5]. - Key management members bring extensive experience in financial control and capital operations, aligning with the company's long-term focus on the pharmaceutical internet sector [5]. Group 5: Future Outlook - The board's capital perspective and the management team's execution capabilities are expected to complement each other, positioning the company for growth and breakthroughs in new market environments [6].

证券日报网讯 7月30日晚间，药易购发布公告称，公司第四届董事会第一次会议审议通过了《关于选举 公司董事会董事长的议案》等多项议案。 （文章来源：证券日报） ...

证券代码：300937 证券简称：药易购 公告编号：2025-034 2、本次股东大会未涉及变更以往股东大会已通过决议的情形。 四川合纵药易购医药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形。 一、会议召开和出席情况 （一）会议召开时间 1、现场会议时间：2025 年 7 月 30 日（星期三）14:30 2、网络投票时间：2025 年 7 月 30 日（星期三） 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 7 月 30 日 9:15-9:25，9:30-11:30，13:00-15:00。 通过深圳证券交易所互联网投票系统进行投票的具体时间为：2025 年 7 月 30 日 9:15-15:00 期间的任意时间。 （二）召开地点：成都市温江区天府金府路中段 51 号药易购温江总部凌霄 书院会场 （三）召开方式：采取现场投票与网络投票相结合的方式 （四）会议召集人：四川合纵药易购医药股份有限公司（以下简称"公 司"）董事会 （五）会议主持 ...

四川合纵药易购医药股份有限公司 内部审计制度 第一章 总则 第一条 为加强四川合纵药易购医药股份有限公司 （以下简称"公司"）内 部审计工作，提升内部审计工作质量，防范和控制公司风险，充分发挥内部审计 作用，维护公司和全体股东合法权益，根据《中华人民共和国公司法》《中华人 民共和国证券法》《中华人民共和国审计法》《审计署关于内部审计工作的规定》 《企业内部控制基本规范》等相关法律、法规、规范性文件和公司章程的规定， 第二条 本制度所称内部审计，是指公司内部审计机构（即审计监察部）对 公司内部控制和风险管理的有效性、财务信息的真实性和完整性以及经营活动的 效率和效果等开展的一种独立、客观的监督和评价活动。 第三条 本制度所称内部控制，是指公司董事会、董事会审计委员会（以下 简称"审计委员会"）、高级管理人员和全体员工为实现下列目标而提供合理保 证的过程： （一）遵守法律、法规、规章及其他相关规定； （二）提高公司经营的效率和效果； （三）保障公司资产的安全和完整； （四）确保公司公开信息的真实、准确、完整和公平。 公司董事会应当对内部控制相关制度的建立健全和有效实施负责。 第四条 本制度适用于公司各部门、分公司 ...

证券代码：300937 证券简称：药易购 公告编号：2025-035 四川合纵药易购医药股份有限公司 第四届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 四川合纵药易购医药股份有限公司（以下简称"公司"）第四届董事会第一 次会议于 2025 年 7 月 30 日在公司会议室以现场结合通讯方式召开，经全体与会 董事一致同意豁免本次会议通知期限。本次董事会会议的通知于 2025 年第一次 临时股东大会结束后，以口头、电话方式通知全体董事。会议应出席董事 9 名， 实际出席董事 9 名，其中董事周跃武、柴俊武以通讯方式出席。本次董事会会议 由半数以上董事共同推举董事赵培培女士主持，公司高级管理人员列席了本次会 议。本次会议的召集、召开和表决程序符合国家有关法律、行政法规、部门规章、 规范性文件及《四川合纵药易购医药股份有限公司章程》（以下简称"《公司章 程》"）的规定。 二、董事会会议审议情况 经与会董事审议，以投票表决方式审议了以下议案： 1、审议通过《关于选举公司董事会董事长的议案》 1 委员会，为保证公司新一 ...